In Macedo et al.'s meta‐analysis to evaluate this aspect, 2177 female patients with metastatic or locally advanced breast cancer treated with anthracyclines and HER‐2 agents were enrolled. This evidence concerns the gene ERBB2 and breast carcinoma.